CD30L-ETA': A new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 2, 1999, Pages 69-77

  Barth, Stefan ^a   Matthey, Bärbel ^a   Huhn, Michael ^a   Diehl, Volker ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

CD30; Hodgkin's disease; Immunotherapy; Recombinant immunotoxin

Indexed keywords

ARGININE; BACTERIAL TOXIN; CD30 ANTIGEN; CD30L ETA ANTIGEN; COMPLEMENTARY DNA; GLUTATHIONE; HYBRID PROTEIN; IMMUNOTOXIN; LEUCINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BURKITT LYMPHOMA; CANCER CELL CULTURE; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ION EXCHANGE CHROMATOGRAPHY; ISOTOPE LABELING; OXIDATION REDUCTION REACTION; PLASMID; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PURIFICATION; PSEUDOMONAS AERUGINOSA;

EID: 0032782134     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Engert A, Diehl V, Schnell R et a, A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood (1997) 89: 403-10.
2. Barth S, Schnell R, Diehl V, Engert A, Development of immunotoxins for potential clinical use in Hodgkin's disease. Ann Oncol (1996) 7: 135-41.
3. Schwab U, Stein H, Gerdes J et al, Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 299: 65-7.
4. Dürkop H, Latza U, Hummel M et al, Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell (1992) 68: 421-7.
5. Smith CA, Gruss HJ, Davis T et al, CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell (1993) 73: 1349-60.
6. Wiley SR, Goodwin RG, Smith CA, Reverse singaling via CD30 ligand. J Immunol (1996) 157: 3635-9.
7. Sahin U, Hartmann F, Senter P et al, Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res (1990) 50: 6944-8.
8. Terenzi A, Bolognesi A, Pasqualucci L et al, Anti-CD30 (BerH2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumor activity against CD30+ tumor cells in vitro and in SCID mice. Br J Haematol (1996) 92: 872-9.
9. Engert A, Burrows F, Jung W et al, Evaluation of ricin A-chain containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin's disease. Cancer Res (1990) 50: 84-8.
10. Schnell R, Linnartz C, Katouzi AA et al, Development of new ricin A-chain immunotoxins with potent anti-tumor effects against Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer (1995) 63: 238-44.
11. Pasqualucci L, Flenghi L, Terenzi A et al, Immunotoxin therapy of hematological malignancies. Haematologica (1995) 80: 546-56.
12. Klimka A, Barth S, Matthey B et al, An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer (1999): in press.
13. Kreitman RJ, Pastan I, Recombinant toxins. Adv Pharmacol (1994) 28: 193-219.
14. Studier FW, Moffatt BA, Use of bacteriophage T7 polymerase to direct selective high-level expression of cloned genes. J Mol Biol (1986) 189: 113-30.
15. Matthey B, Engert A, Klimka A et al, A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene (1999): in press.
16. Wels W, Harweth IM, Mueller M et al, Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res (1992) 52: 6310-17.
17. Sambrook J, Fritsch EF, Maniatis T, Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, New York, 1989.
18. Kapp U, Wolf J, von Kalle C et al, Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. Ann Oncol (1992) 3: 21-3.
19. Lenoir GM, Vuillaume M, Bonnardel C, The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma. In: Burkitt's Lymphoma, A Human Cancer Model (ed G Lenoir, G O'Connor, CLM Olweny) 309-18. IARC Scientific Publications, Lyon, 1985.
20. Sims JE, March CJ, Cosman D et al, cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science (1988) 241: 585-9.
21. Plaksin D, Chacko S, McPhie P et al, A T cell receptor Vα domain expressed in bacteria: Does it dimerize in solution? J Exp Med (1996) 184: 1251-8.
22. 1) shows specific cytotoxicity against IL-9-receptor-expressing cell lines. Cytokines Mol Ther (1996) 2: 139-46.
23. Galloway DR, Hedstrom RC, Pavlovskis OR, Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa. Infect Immun (1984) 44: 262-7.
24. Pfreundschuh M, Mommertz E, Meissner M et al, Hodgkin and Reed-Sternberg cell associated monoclonal antibodies HRS-1 and HRS-2 react with activated cells of lymphoid and monocytoid origin. Anticancer Res (1988) 8: 217-24.
25. + Hodgkin-derived cell lines. Int J Mol Med (1998) 1: 249-56.
26. Powell IF, Li T, Jäck HM, Ellis TM, Construction and expression of a soluble form of human CD30 ligand with functional activity. J Leuk Biol (1998) 63: 752-7.
27. Falini B, Pileri S, Pizzolo G et al, CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood (1995) 85: 1-14.
28. Vitetta E, Thorpe PE, Uhr JW, Immunotoxins: magic bullets or misguided missiles? Immunol Today (1993) 14: 252-9.
29. Grossbard ML, Gribben JG, Freedman AS et al, Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone-marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood (1993) 81: 2263-71.